Ovarian Neoplasms (C04.588.322.455); Physical Examination (E01.370.600); Ovarian Cysts (C04.182.612); Fallopian Tube Diseases (C13.351.500.056.390)
Gout (C05.550.114.423); Gout (C05.799.414); Gout (C16.320.565.798.368); Gout (C18.452.648.798.368); Uricosuric Agents (D27.505.954.329.337.900); Gout Suppressants (D27.505.954.329.337); Therapeutic Uses (D27.505.954); Pharmacologic Actions (D27.505); Anti-Inflammatory Agents; Non-Steroidal (D27.505.696.663.850.014.040.500); Anti-Inflammatory Agents; Non-Steroidal (D27.505.954.158.030); Anti-Inflammatory Agents; Non-Steroidal (D27.505.954.329.030); Steroids (D04.808); Xanthine Oxidase (D08.811.682.047.928); Allopurinol (D03.438.759.160); Colchicine (D03.132.225); Prednisolone (D04.808.745.432.769.795); Ibuprofen (D02.241.223.701.430); Naproxen (D02.455.426.559.847.638.472.500); Naproxen (D04.615.638.472.450); Diclofenac (D02.241.223.601.210); Indomethacin (D03.438.473.420); Cyclooxygenase 2 Inhibitors (D27.505.519.389.310.500); Cyclooxygenase 2 Inhibitors (D27.505.696.663.850.014.040.500.500.500); Cyclooxygenase 2 Inhibitors (D27.505.954.158.030.500.500); Cyclooxygenase 2 Inhibitors (D27.505.954.329.030.500.500); Methylprednisolone (D04.808.745.432.769.795.539); Probenecid (D02.065.884.625); Probenecid (D02.886.590.700.625)
group of mesh terms